An innovative brain imaging study combined Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (fMRI) to characterize the labeling and functional connectivity of NLX-112 and NLX-101. Both compounds are highly selective for serotonin 5-HT1A receptors but exhibit preferential interaction (or 'biased agonism') at specific receptor sub-populations. NLX-112 is being developed for treatment of dyskinesia in Parkinson's disease, whereas NLX-101 is a candidate for treatment of Rett syndrome. The imaging study was carried out at the Lyon Neuroscience Research Center (France) by the team of Prof. Luc Zimmer, with whom Neurolixis has a long-standing collaboration.

In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.